Back to top
more

Pfizer (PFE)

(Delayed Data from NYSE)

$26.27 USD

26.27
24,538,403

-0.05 (-0.19%)

Updated Apr 24, 2024 04:00 PM ET

After-Market: $26.18 -0.09 (-0.34%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 11% (224 out of 252)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for PFE

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

Fiscal Year End for Pfizer Inc falls in the month of December.

All items in Millions except Per Share data.

12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Assets          
Cash & Equivalents 12,690 22,732 31,069 12,221 9,830
Receivables 11,177 10,952 11,479 7,930 8,724
Notes Receivable 0 0 0 0 0
Inventories 10,189 8,981 9,059 8,046 8,283
Other Current Assets 9,277 8,594 8,086 6,869 5,965
Total Current Assets 43,333 51,259 59,693 35,067 32,803
Net Property & Equipment 18,940 16,274 14,882 13,900 13,967
Investments & Advances 15,368 15,069 21,526 20,262 20,147
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 3,706 6,693 3,341 2,383 2,099
Intangibles 132,683 94,745 74,354 78,048 94,023
Deposits & Other Assets 12,471 13,163 7,679 4,569 4,450
Total Assets 226,501 197,205 181,476 154,229 167,489
Liabilities & Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Notes Payable 0 2,945 2,241 2,703 16,195
Accounts Payable 6,710 6,809 5,578 4,309 4,220
Current Portion Long-Term Debt 10,350 2,945 2,241 2,703 16,195
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 2,776 3,407 3,332 3,058 2,720
Income Taxes Payable 2,349 1,587 1,266 1,049 980
Other Current Liabilities 25,609 27,391 30,255 14,802 13,187
Total Current Liabilities 47,794 42,138 42,671 25,920 37,304
Mortgages 0 0 0 0 0
Deferred Taxes/Income 640 1,023 349 4,063 5,578
Convertible Debt 0 0 0 0 0
Long-Term Debt 61,538 32,884 36,195 37,133 35,955
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 27,240 25,242 24,798 23,640 25,205
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 137,213 101,288 104,013 90,756 104,042
Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Preferred Stock 0 0 0 0 17
Common Stock (Par) 478 476 473 470 468
Capital Surplus 92,631 91,802 90,591 88,674 87,428
Retained Earnings 118,353 125,656 103,394 96,770 97,670
Other Equity -7,687 -8,048 -5,635 -11,453 -11,337
Treasury Stock 114,487 113,969 111,361 110,988 110,801
Total Shareholder's Equity 89,288 95,916 77,462 63,473 63,447
Total Liabilities & Shareholder's Equity 226,501 197,205 181,476 154,229 167,489
Total Common Equity 89,288 95,916 77,462 63,473 63,430
Shares Outstanding 5,646.40 5,613.30 5,612.80 5,558.40 5,534.10
Book Value Per Share 15.81 17.09 13.80 11.42 11.46

Fiscal Year End for Pfizer Inc falls in the month of December.

All items in Millions except Per Share data.

3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Assets          
Cash & Equivalents -99,999 12,690 44,181 44,785 19,972
Receivables NA 11,177 11,086 10,231 12,305
Notes Receivable NA 0 0 0 0
Inventories NA 10,189 10,204 10,310 9,541
Other Current Assets NA 9,277 8,541 8,022 8,260
Total Current Assets NA 43,333 74,012 73,347 50,078
Net Property & Equipment NA 18,940 17,862 17,488 17,052
Investments & Advances NA 15,368 14,239 15,066 14,743
Other Non-Current Assets NA 0 0 0 0
Deferred Charges NA 3,706 8,350 8,261 7,302
Intangibles NA 132,683 91,751 92,978 93,478
Deposits & Other Assets NA 12,471 8,808 13,028 12,965
Total Assets NA 226,501 215,021 220,168 195,617
Liabilities & Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Notes Payable NA 0 0 3,985 4,188
Accounts Payable NA 6,710 5,338 6,081 6,123
Current Portion Long-Term Debt NA 10,350 2,548 3,985 4,188
Current Portion Capital Leases NA 0 0 0 0
Accrued Expenses NA 2,776 2,372 1,972 2,277
Income Taxes Payable NA 2,349 1,898 2,928 1,969
Other Current Liabilities NA 25,609 18,980 19,680 22,005
Total Current Liabilities NA 47,794 31,136 34,647 36,562
Mortgages NA 0 0 0 0
Deferred Taxes/Income NA 640 1,125 1,232 1,067
Convertible Debt NA 0 0 0 0
Long-Term Debt NA 61,538 61,048 61,356 31,704
Non-Current Capital Leases NA 0 0 0 0
Other Non-Current Liabilities NA 24,507 23,639 25,048
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities NA 137,213 117,817 120,875 94,381
Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Preferred Stock NA 0 0 0 0
Common Stock (Par) NA 478 478 478 478
Capital Surplus NA 92,631 92,496 92,329 92,153
Retained Earnings NA 118,353 126,411 128,796 131,102
Other Equity NA -7,687 -7,696 -7,828 -8,023
Treasury Stock NA 114,487 114,485 114,482 114,473
Total Shareholder's Equity NA 89,288 97,204 99,293 101,236
Total Liabilities & Shareholder's Equity NA 226,501 215,021 220,168 195,617
Total Common Equity 0 89,288 97,204 99,293 101,236
Shares Outstanding 5,662.50 5,646.40 5,645.90 5,645.30 5,644.40
Book Value Per Share 0.00 15.81 17.22 17.59 17.94